The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited gram-negative infection (GNI) armamentarium. Despite the launch of antibiotics such as Avycaz / Zavicefta, Zerbaxa, Vabomere, Xerava, and Zemdri, unmet needs remain for additional effective treatment options. Commercial opportunities exist for emerging therapies with efficacy in patients with drug-resistant infections, especially those associated with high rates of mortality. However, the market is heavily genericized, and cost containment measures may limit commercial success.
Geographies: United States, EU5, Japan
Primary Research: More than 20 country-specific interviews with thought-leading infectious diseases specialists supported by survey data collected for this and other DRG research.
Epidemiology: Diagnosed events of GNIs, segmented by key indications (NP, cSSSIs/SSIs, BSIs, cIAIs, UTIs), pathogens (E. coli, Pseudomonas, Acinetobacter, Klebsiella), resistance, and country.
FORECAST: Ten-year, annualized, drug-level sales and patient share of key GNI therapies through 2028, segmented by brands / generics, geography, and five key indications.
Emerging Therapies: Phase III / PR: 11 drugs. Phase II: 4 drugs; coverage of select preclinical and Phase I products
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.